期刊文献+

Stathmin蛋白在大肠癌中的表达及临床意义 被引量:3

Expression of Stathmin in colorectal carcinoma and its clinical significance
下载PDF
导出
摘要 目的:探讨Stathmin蛋白在大肠癌中的表达及其与肿瘤病理特征的关系。方法:采用免疫组织化学SP法检测56例大肠癌组织Stathmin蛋白的表达,同时选取16例大肠腺瘤组织作对照。结果:Stathmin蛋白在大肠癌中的阳性表达率为60.7%(34/56),明显高于大肠腺瘤组织的31.3%(5/16),P<0.05。Stathmin蛋白表达与肿瘤部位、大小、分化程度、Duke's临床分期及淋巴结转移均无明显相关,P>0.05。结论:Stathmin蛋白过表达与大肠癌的发生密切相关,但它不能作为判断大肠癌恶性程度的指标。 Objective:To explore the expression of Stathmin protein in colorectal carcinoma and its relation to clinicopathologic features.Methods:The Stathmin protein levels in 56 cases of colorectal carcinoma and 16 cases of colorectal adenoma were detected by immunohistochemistry method.Results:The positive rates of Stathmin in colorectal carcinoma(34/56,60.7%) significantly higher than those in colorectal adenoma(5/16,31.3%),P 0.05.The positive expression of Stathmin was not associated with tumor size,location,differentiation,Duke's stage and lymphnode metastasis.Conclusion:Stathmin may play a role in the carcinogenesis of colorectal carcinoma,but it is not a good marker for evaluation of tumor biological features.
出处 《现代肿瘤医学》 CAS 2010年第12期2408-2410,共3页 Journal of Modern Oncology
基金 广东省自然科学基金(No031963)
关键词 STATHMIN 结直肠癌 免疫组织化学 Stathmin colorectal carcinoma immunohistochemistry
  • 相关文献

参考文献12

  • 1Rana S,Maples PB,Senzer N,et al.Stathmin 1:a novel therapeutic target for anticancer activity[J].Expert Rev Anticancer Ther,2008,8(9):1461-1470.
  • 2Iancu C,Mistry SJ,Arkin S,et al.Taxol and anti-stathmin therapy:a synergistic combination that targets the mitotic spindle[J].Cancer Res,2000,60(13):3537-3541.
  • 3Wang R,Dong K,Lin F,et al.Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-midiated downregulation of stathmin expression[J].Mol Med,2007,13(11-12):567-575.
  • 4Sadow PM,Rumilla KM,Erickson LA,et al.Stathmin expression in pheochromocytomas,paragangliomas,and in other endocrine tumors[J].Endocr Pathol,2008,19(2):97-103.
  • 5王琰,王中彬,哈敏文.非小细胞肺癌组织中stathmin、p53蛋白表达及其临床意义[J].山东医药,2009,49(14):22-24. 被引量:3
  • 6Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 7Zhang HZ,Wang Y,Gao P,et al.Silencing stathmin gene expression by surviving promoter-driven sirna vector to reverse malignant phenotype of tumor cells[J].Cancer Biol Ther,2006,5(11):1457-1461.
  • 8Carney BK,Cassimeris L.Stathmin/oncoprotein 18,a microtubule regulatory protein,is required for survival of both normal and cancer cell lines lacking the tumor suppressor,p53[J].Cancer Biol Ther,2001,9(9):697-708.
  • 9Xi W,Rui W,Fang L,et al.Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients[J].J Cancer Res Clin Oncol,2009,135(6):837-846.
  • 10Jeon TY,Han ME,Lee YW,et al.Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells[J].Br J Cancer,2010,102(4):710-718.

二级参考文献9

  • 1张东,刘长庭.抑癌基因p53对非小细胞肺癌化疗药物敏感性的影响[J].军医进修学院学报,2005,26(3):236-237. 被引量:4
  • 2韩宝惠.药物基因组学研究与肺癌个体化治疗[J].中华肿瘤防治杂志,2007,14(11):801-804. 被引量:6
  • 3Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer [ J]. Mol Cancer Ther,2005,4( 12 ) : 1821-1829.
  • 4Alli E, Yang JM, Ford JM, et al. Reversal of stathmin-mediated resistance to paelitaxel and vinblastine in human breast carcinoma cells [ J]. Mol Pharmacol,2007,71 ( 5 ) : 1233-1240.
  • 5Zada A, Geletu M, Pulikkan J, et al. Proteomic analysis of acute promyelocytic leukemia:PML-RARα leads to decreased phosphorylation of OP18 at sefine 63[J]. Proteomics,2006,6(21 ) :5705-5719.
  • 6Mistry SJ, Bank A, Atweh GF. Synergistic antiangiogenie effects of stathmin inhibition and taxolexposure[ J]. Mol Cancer Res,2007,5 (8) :773-782.
  • 7Singer S, Ehemann V, Br'auekhoff A, et al. Protumorigenie overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocareinogenesis [ J ]. Hepatology, 2007,46 ( 3 ) : 759- 768.
  • 8Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression,early recurrence,and poor prognosis in hepatocellularcarcinoma[ J]. J Pathol,2006,209(4) :549-558.
  • 9罗扬(综述),冯奉仪(审校).药物基因组学在晚期非小细胞肺癌治疗中的应用[J].国际肿瘤学杂志,2007,34(9):696-698. 被引量:1

共引文献2

同被引文献23

  • 1李航,钟志鸿,杨进,董靖.海马突触可塑性与创伤后应激障碍(PTSD)相关研究[J].基因组学与应用生物学,2015,34(3):658-662. 被引量:11
  • 2王潇,樊青霞,赵培荣,王峰.微管不稳定蛋白Stathmin在食管鳞癌组织中的表达及意义[J].肿瘤基础与临床,2007,20(5):372-374. 被引量:8
  • 3Fattaneh AT, Peter D. Pathology and genetics of tumors of breast and female genital organs[MJ. IARC Press:Lyon,2003.
  • 4Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op 181 stathmin downstream of Racl[J]. 1 Bioi Chem,2004,279(7) :6196 -6203.
  • 5Wang F, Wang LX, Li SL, et al, Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma[J] . 1 Surg Oncol, 2011 , 103 (7) :704 -715.
  • 6Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle[1J .J Cell Biochem, 2004 ,93 (2) : 242 - 250.
  • 7Mikael ES, Per H, Sonja S, et al. Global regulation of the interphase microtubule system by abundantly expressed Opl81 stathmin[1J . Mol Bioi Cell, 2008 , 19 ( 7) : 2897 - 2906.
  • 8Doye V, Kellermann 0, Buc-Caron MH, et al , High expression of Stathmin in multi potential teratocarcinoma and normal embryonic cells versus their early differentiated derivatives[1J. Differentiation, 1992 ,50 ( 2) : 89 - 96.
  • 9Kim 1Y, Harvard C, You L, et al. Stathmin is overexpressed in malignant mesothelioma[1J. Anticancer Res, 2007 , 27 ( I A ) : 39 -44.
  • 10Trovik 1, Wik E, Stefansson 1M, et al: Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer[1J . Clin Cancer Res, 20 II , 17 ( 10) : 3368 - 3377.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部